Thomas R Staab II bought $11k of TENX
Chief Financial Officer at TENAX THERAPEUTICS, INC.. 5,675 shares at an average of $1.94, traded Sep 11, 2026, filed Sep 15, 2026.
Score components
- +22RoleCFO
- 0Trade size$11k at market
- +10Relative to holdingsHoldings up 57%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-392319, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | POpen-market purchase Common Stock | +5,675 | $1.94 | $11k | 15,675 | 27 d ago |
Related signals
Other insiders at TENAX THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | TENAX THERAPEUTICS, INC. | Declan Doogan director | $102k 53,000 shares | +2331% | |
| 50Moderate | TENAX THERAPEUTICS, INC. | Christopher Thomas Giordano CEO | $20k 10,850 shares | +96% | |
| 55Moderate | TENAX THERAPEUTICS, INC. | ADAR1 Capital Management, LLC owner | $1.6M 900,000 shares | +16% | |
| 50Moderate | TENAX THERAPEUTICS, INC. | ADAR1 Capital Management, LLC owner | $1.4M 770,333 shares | +16% | |
| 23Weak | TENXbuy TENAX THERAPEUTICS, INC. | June Sherie Almenoff director | $15k 1,993 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.